All News

FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines
May 27, 2025

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Novel 5-HT2A Agonist GM-2505 Achieves 94% Remission Rate in Phase 2a MDD Trial, With Rapid and Durable Efficacy
May 27, 2025

The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.

Telehealth May Represent Up to 30% of US Medical Visits by 2026
May 27, 2025

Telemedicine's trajectory depends far more on future regulatory action than on health care's readiness or patient desire, according to a new report.

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study
May 27, 2025

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

FDA Clears First At-Home Pap Smear Alternative for Cervical Cancer Screening: Daily Dose
May 27, 2025

Your daily dose of the clinical news you may have missed.

Combined Oral Contraceptive Use May Triple the Risk of Cryptogenic Stroke in Young Women
May 23, 2025

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype
May 23, 2025

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Colonoscopy Completion Up 69% With Patient Navigation Program After FIT: Daily Dose
May 23, 2025

Your daily dose of the clinical news you may have missed.

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care
May 22, 2025

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

Roflumilast Topical Foam 0.3% Approved to Treat Plaque Psoriasis in People Aged 12 Years and Older
May 22, 2025

Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.